ReviewBiology direct2026
Microvesicles, exosomes and their combinations with cytoplasmic organelles: from their discovery to their innovative roles in clinical medicine.
Review in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular vesicles as therapeutic agents for retinal ganglion cell degeneration: current challenges and future prospects.International ophthalmology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular Vesicles (EVs), two types of different size: microvesicles and exosomes, generated by all types of cells. EV interactions with lysosomes and/or autophagosomes, induce establishment of combined forms. EVs are composed by a surface membrane of lipid bilayer rich of specific proteins around a cargo with distinct lipids and proteins together with various forms of RNA. This review illustrates the whole life of EVs, from their intracellular generation followed by their release to their extracellular space. The ensuing EV navigations lead to binding/penetration into cells and solid/fluid organs, selected based on specific markers, receptors and metabolism. Modified EVs undergo release with binding to other vesicles accompanied by regeneration of recycling to appropriate cells, at some distance or even far away from their origin/establishments. By action with interactive cells, EVs may induce either health processes or various events of diseases, often employed for diagnosis and interest of patients. By acting especially on stem cells of mesenchymal and cancer nature, EVs induce changes of brain, heart, immunology and other diseases, especially cancer. Upon appropriate engineering various EVs, possibly converted into artificial nanovesicles, undergo loading and traffic of drugs and nanomaterials. These and other factors strengthen the EV therapy by ensuing dynamics in critical cancer conditions. A fraction of EV investigation can be converted into established medical employment by confirmed clinical trials. At present, established conversions are progressed towards direct treatments. Ongoing innovative/promising developments are planned, established for future research and therapies.Clinical trial number Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.